We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients ...

Daiichi Sankyo phase 1 study of patritumab deruxtecan demonstrates tumor response across multiple resistance mechanisms in patients with advanced EGFR-mutated NSCLCWhile the efficacy of targeted ...

DATROWAY DATROWAY (datopotamab deruxtecan-dlnk in the US; datopotamab deruxtecan in rest of world) is a TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, DATROWAY is ...

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial ...

Notably, T-DXd demonstrated activity across HER2-low and ultralow categories, supporting its use in patients with any detectable HER2 expression. T-DXd's unique mechanism helps explain this broad ...

WILMINGTON, Del., January 13, 2025--AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in ...